Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment

Stopped early · Not applicable

Conditions studied: Myopia

In brief

The purpose of the present study is to carry out a trial to evaluate the clinical efficacy of the NeuroVision Low Myopia Treatment. The specific questions to be answered are: 1. Is there an improvement in vision following the treatment without bringing about a change in the subject's prescription for glasses? 2. Can any treatment effect be seen at 6 months and 12 months after the termination of the treatment?

Key facts

Study ID

NCT00469612

Run by

Ohio State University

People needed

2

Starts

2007-06-01

Expected to finish

2009-12-01

Last updated by the study team

2018-09-25

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age should be between 18 to 59 years
• Spherical equivalent in the worst eye should not exceed -1.5 DS and the astigmatism should not exceed -0.75 DC.
• The subject's refractive status is stable, with no increase beyond 0.5D in sphere or cylinder over the last six months. That is, the subject's spectacle prescription should not differ from the auto-refraction value by 0.50D.
• Unaided visual acuity is 0.6 LogMAR or better in the eye with the poorer unaided acuity
• Unaided visual acuity is 0.1 LogMAR or worse in the eye with better unaided acuity
• Unaided visual acuity difference between both eyes is less than 0.3 LogMAR
• Best-corrected visual acuity is 0.04 LogMAR or better in both eyes.
• The subject should be aware that the study has the following features:
• The recommended pace for the treatment sessions is at least 3 sessions per week.
• Interruptions should not be longer than 2 weeks during the treatment course. Note: The subject is free to voluntarily withdraw from the study at any time.

You may not qualify if…

• The subject suffers from any other visually disabling eye disease(s) or other causes for the reduced visual acuity, aside from myopia and/or astigmatism
• The subject suffers from myopia-related visual complications resulting in visual loss, including myopic macular degeneration, myopic cataract and previous or pre-existing myopic retinal detachment.
• The subject is suffering from Diabetes Mellitus.
• The subject suffers from Migraines
• The subject suffers from Epilepsy
• The subject is pregnant. (It is not recommended to include pregnant women because of the expected visual fluctuations. The NV treatment , basically using a computer, has no impact on the pregnancy.) No pregnancy testing will be done but will be identified through verbal history. The study has use of tropicamide drug (dilation drops) and proparacaine (topical anesthetic), which are a routinely used eye drop in everyday clinical practice and no adverse effects have been reported so far on pregnant women or fetus.
• The subject has an activity limitation due to medical disorders (including migraines, seizure disorders, etc.), medications, or emotional status that might potentially impair the subject's ability to perform the treatment.

Where it is running

• College of Optometry, The Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.